Hormone Receptor Positive Tumor Clinical Trials

9 recruitingLast updated: June 17, 2026

There are 9 actively recruiting hormone receptor positive tumor clinical trials across 25 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Houston, Texas, United States, Los Angeles, California, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Hormone Receptor Positive Tumor Trials at a Glance

9 actively recruiting trials for hormone receptor positive tumor are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Dallas. Lead sponsors running hormone receptor positive tumor studies include Fudan University, Incyclix Bio, and Barbara Ann Karmanos Cancer Institute.

Browse hormone receptor positive tumor trials by phase

Treatments under study

About Hormone Receptor Positive Tumor Clinical Trials

Looking for clinical trials for Hormone Receptor Positive Tumor? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Receptor Positive Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Receptor Positive Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor+1 more
SOLTI Breast Cancer Research Group96 enrolled15 locationsNCT05982093
Recruiting
Not Applicable

A Study of the TheraBionic P1 Device in Breast Cancer

HER2-negative Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Barbara Ann Karmanos Cancer Institute24 enrolled8 locationsNCT07218432
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

HER2-negative Breast CancerEarly Breast CancerHormone Receptor Positive Tumor
Institute of Oncology Ljubljana319 enrolled1 locationNCT06650423
Recruiting
Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095